Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

WK Physicians Network

Neither a doctor nor a teaching hospital

Research payments

$14,450,486

346 payments

Through program year 2025, WK Physicians Network is reported as receiving $14,450,486 in research payments, across 346 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $95,785 14
2024 Research $48,156 10
2023 Research $1,972,898 32
2022 Research $629,623 28
2021 Research $6,560,424 56
2020 Research $4,753,452 45
2019 Research $390,147 161

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $12,307,115 63 payments
  2. AstraZeneca Pharmaceuticals LP $953,308 23 payments
  3. GlaxoSmithKline, LLC. $337,837 22 payments
  4. Ipsen Bioscience Inc $221,546 9 payments
  5. AstraZeneca UK Limited $119,619 7 payments
  6. Novavax Inc $114,794 8 payments
  7. Boston Scientific Corporation $83,315 24 payments
  8. Alcon Research LLC $68,034 149 payments
  9. AbbVie, Inc. $66,991 9 payments
  10. Merck Sharp & Dohme Corporation $64,602 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $11,728,307 50 payments
  2. A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $571,308 12 payments
  3. A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma $449,806 6 payments
  4. A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Thera $337,837 22 payments
  5. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) $308,147 10 payments
  6. This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency HRD tumor status and with platinum sensitive relapsed high grade ovarian cancer Subjects should have received at least 2 prior lines of platinum based chemotherapy $158,945 4 payments
  7. An Open-label Randomised Multicentre Phase III Study of Irinotecan Liposome Injection Oxaliplatin 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas $121,801 2 payments
  8. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation $121,265 8 payments
  9. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) $114,794 8 payments
  10. An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas $79,673 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record